




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : <b>A61K 31/40, 31/445</b>		<b>A1</b>	(11) International Publication Number: <b>WO 90/14826</b>
			(43) International Publication Date: 13 December 1990 (13.12.90)
(21) International Application Number: PCT/GB90/00866 (22) International Filing Date: 6 June 1990 (06.06.90) (30) Priority data: 8912935                      6 June 1989 (06.06.89)                      GB 2/96045                      9 April 1990 (09.04.90)                      JP (71) Applicant (for all designated States except JP US): FISON'S PLC [GB/GB]; Fison House, Princes Street, Ipswich, Suffolk IP1 1QH (GB). (71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL COMPANY LIMITED [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only) : NORRIS, Alan, Anthony [GB/GB]; 28 Pitsford Drive, Loughborough, Leicestershire LE11 0NZ (GB). JACKSON, Dale, Michael [GB/GB]; 23 The Green, Diseworth, Derbyshire DE7 2QN (GB). MAKINO, Sohei [JP/JP]; 4-5-14, Midorimachi, Mibu-cho, Shimotsuga-gun, Tochigi 321-02 (JP). FUKUDA, Takeshi [JP/JP]; 1704-41, Tsuruta, Utsunomiya-shi, Tochigi 320 (JP). AKUTSU, Ikuo [JP/JP]; 4-12-1207, Mutsumimachi, Utsunomiya-shi, Tochigi 320 (JP).			(74) Agent: WRIGHT, Robert, Gordon, McRae; Fisons plc, 12 Derby Road, Loughborough, Leicestershire LE11 0BB (GB). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), US. Published With international search report.

(54) Title: MACROLIDES FOR THE TREATMENT OF REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASES



(57) Abstract

Compounds of formula (I), wherein R<sup>1</sup> and R<sup>2</sup> together represent two vicinal hydrogen atoms, or form a second bond between the vicinal carbon atoms to which they are attached; R<sup>3</sup> represents H, OH, alkoxy or protected hydroxy; R<sup>4</sup> represents OH; R<sup>5</sup> represents H, alkyl or alkenyl; R<sup>6</sup> and R<sup>7</sup> independently represent O, (H,OH), (H,protected hydroxy) or (H,alkoxy). X and Y independently represent O, (H,OH) or (H,H); n is 1 or 2; or pharmaceutically acceptable derivatives thereof; provided for the treatment of reversible obstructive airways disease, particularly asthma. Compositions containing such compounds are also disclosed.

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LJ	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TC	Togo
DK	Denmark			US	United States of America

- 1 -

Macrolides for the treatment of reversible obstructive airways diseases.


This invention relates to a novel treatment of reversible obstructive airways disease, more particularly to the use of macrocyclic compounds in the treatment of reversible obstructive airways disease, and to compositions containing such compounds.

European Patent Application 184162 (to Fujisawa Pharmaceuticals Co Ltd) discloses several macrolides (numbered FR-900506, FR-900520, FR-900523 and FR-900525) and derivatives thereof which are isolated from microorganisms belonging to the genus Streptomyces. The macrolides are indicated as immunosuppressive agents. European Patent Application 323042 (to Fisons plc) discloses many macrolides which may be derived from those disclosed in European Patent Application 184162. Again, the compounds are primarily indicated as immunosuppressive agents. European Patent Applications 349049 and 349061 (to Merck & Co Inc, published after the priority date of the present invention) disclose the dihydroxycyclohexyl derivatives of FR-900506 and FR-900520 respectively and indicate them primarily as immunosuppressive agents. None of the documents mentioned above discloses or suggests the use of the compounds disclosed in the treatment of reversible obstructive airways disease.

We have now surprisingly found that a number of macrocyclic compounds, including some of those disclosed in the documents mentioned above (which are herein incorporated by reference), are efficacious in the

treatment of reversible obstructive airways disease.

Thus, according to the present invention, we provide the use of a compound of formula I,



wherein  $R^1$  and  $R^2$  together represent two vicinal hydrogen atoms, or form a second bond between the vicinal carbon atoms to which they are attached;

20  $R^3$  represents H, OH, alkoxy or protected hydroxy;

$R^4$  represents OH;

$R^5$  represents H, alkyl or alkenyl;

$R^6$  and  $R^7$  independently represent O, (H,OH), (H,protected hydroxy) or (H,alkoxy);

25 X and Y independently represent O, (H,OH) or (H,H);

n is 1 or 2;

or a pharmaceutically acceptable derivative thereof;

as active ingredient in the manufacture of a

medicament for the treatment of reversible obstructive airways disease.

European Patent Application No 327009 (to Fujisawa Pharmaceuticals Co Ltd, published after the priority date of the present invention) discloses the use of two compounds and their derivatives in the treatment of asthma. Characterising data for the compounds is given, but their structure is not apparent. Should the compounds of European Patent Application No 327009 fall within the scope of formula I above, they are excluded from the present invention.

Preferably, when  $R^3$ ,  $R^5$ ,  $R^6$  and  $R^7$  comprise carbon-containing groups, those groups contain up to 10 carbon atoms, more preferably from 1 to 6, eg methyl or methoxy.


$R^5$  is preferably allyl (ie prop-2-enyl), propyl, ethyl or methyl.

Preferably, n is 2.

Desirably, at least one of  $R^6$  and  $R^7$  represents (H,OH).

We prefer Y to represent O.

The present invention provides the use of all stereoisomers of the compounds of formula I. However, we prefer the compounds of formula I to have the stereochemistry shown in formula Ia:



By the term "protected hydroxy" we mean a group which  
 15 may be treated so as to yield a hydroxy group. Examples of  
 such groups include an oxygen atom bonded to a protecting  
 group selected from the following:

- a) 1-(alkyl C1 to C6 thio)alkyl C1 to C6 such as alkyl C1  
 to C6 thiomethyl (eg methyl thiomethyl, ethylthiomethyl,  
 20 propylthiomethyl, isopropylthiomethyl, butylthiomethyl,  
 isobutylthiomethyl, hexylthiomethyl), preferably alkyl C1  
 to C4 thiomethyl and most preferably methylthiomethyl;
- b) trisubstituted silyl such as tri(alkyl C1 to C6)silyl  
 (eg trimethylsilyl, triethylsilyl, tributylsilyl,  
 25 <sup>t</sup>butyldimethylsilyl, tri-<sup>t</sup>butylsilyl), (alkyl C1 to  
 C6)diarylsilyl (eg methyldiphenylsilyl, ethyldiphenylsilyl,  
 propyldiphenylsilyl, <sup>t</sup>butyldiphenylsilyl), preferably  
 tri(alkyl C1 to C6)silyl and (alkyl C1 to C6)diphenylsilyl,

most preferably <sup>t</sup>butyldimethylsilyl and <sup>t</sup>butyldiphenylsilyl; and

c) acyl such as aliphatic acyl, aromatic acyl and aliphatic acyl substituted with aromatic groups, which are  
5 derived from carboxylic, sulphonic and carbamic acids.

Preferred protected hydroxy groups that may be mentioned include trialkylsilyloxy groups, for example <sup>t</sup>butyldimethylsilyloxy.

Further protecting groups and methods for the  
10 introduction and removal of protecting groups are described in 'Protective Groups in Organic Chemistry', ed: J W F McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', T W Greene, Wiley-Interscience (1981).

Pharmaceutically acceptable derivatives of compounds  
15 of formula I include esters formed between hydroxy groups and carboxylic acids, and salts (for example alkali metal salts) formed with any acidic groups which may be present.

Specific compounds of formula I which may be mentioned include:

20 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo [22.3.1.0<sup>4,9</sup>]octacos-18-ene-2,3,10,16-tetraone,

17-ethyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-  
25 methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxo-4-azatricyclo [22.3.1.0<sup>4,9</sup>]octacos-18-ene-2,3,10,16-tetraone,

17-allyl-1,14-dihydroxy-12-[2-(3,4-dihydroxycyclohexyl)

- . -1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-  
 11,28-dioxa-4-azatricyclo[22.3.1.0<sup>4,9</sup>]octacos-18-ene-  
 2,3,10,16-tetraone,  
 17-ethyl-1,14-dihydroxy-12-[2-(3,4-dihydroxycyclohexyl)  
 5 -1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-  
 11,28-dioxa-4-azatricyclo[22.3.1.0<sup>4,9</sup>]octacos-18-ene-  
 2,3,10,16-tetraone,  
 17-propyl-1-hydroxy-12-[2-(4-hydroxy-3-  
 methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-  
 10 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo  
 [22.3.1.0<sup>4,9</sup>]octacos-18-ene-2,3,10,16-tetraone,  
 17-allyl-1,2,14-trihydroxy-12-[2-(4-hydroxy-3-  
 methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-  
 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo  
 15 [22.3.1.0<sup>4,9</sup>]octacos-18-ene-3,10,16-trione, or  
 17-allyl-1-hydroxy-12-[2-(4-hydroxy-3-  
 methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-  
 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo  
 [22.3.1.0<sup>4,9</sup>]octacos-18-ene-2,3,10,16-tetraone.

20 The term "treatment" as used herein includes prophylaxis as well as relieving the symptoms of disease.

The term "reversible obstructive airways disease" will  
 be well understood by those skilled in the art to include  
 conditions such as asthma, including bronchial asthma,  
 25 allergic asthma, intrinsic asthma, extrinsic asthma and  
 dust asthma, particularly chronic or inveterate asthma (for  
 example late asthma and airway hyper-responsiveness);  
 bronchitis and the like [see for example UK Patent No



2022078 and Brit J. Pharmac (1987), 24, 4983-501]. Of particular interest is asthma.

Administration of the active ingredient may be topical (for example by inhalation to the lung), or systemic (for  
5 example by oral administration to the gastrointestinal tract).

Dealing first with topical administration, those compounds of formula I which are solids at room temperature may be inhaled as a dry powder which may be pressurized or  
10 non-pressurized. In non-pressurized powder compositions, the active ingredient in finely divided form may be used in admixture with a larger sized pharmaceutically acceptable inert carrier comprising particles, eg of up to 100 $\mu$ m diameter. Suitable inert carriers include sugars, for  
15 example crystalline lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range 0.01 to 10 $\mu$ m.

By providing a large proportion of fine particles of active ingredient the invention enables a lower dosage of  
20 drug to be administered and/or for an equivalent amount of drug to produce a greater or longer lasting effect, because fine particles are more likely to penetrate into the deeper regions of the human airways.

The finely divided active ingredient may be made by  
25 grinding or milling and is preferably dried thoroughly before formulation.

Non-pressurized powder compositions preferably contain from 0.2 to 5% by weight, more preferably from 0.5 to 2.5%

- . by weight, and particularly from 1 to 1.5% by weight of the active ingredient, and from 95 to 99.8% by weight, more especially from 98.5 to 99% by weight of the carrier.

The composition may alternatively be pressurized and  
5 contain a compressed gas, eg nitrogen, or a liquefied gas propellant.

In pressurized compositions, the active ingredient is preferably finely divided, eg having a mass median diameter in the range 0.01 to 10 $\mu$ m (and these finely divided  
10 forms of the active ingredient are a feature of the invention). We particularly prefer the active ingredient to have a mass median diameter of less than 4 $\mu$ m and especially of less than 3.0 $\mu$ m and most preferably of less than 2.8 $\mu$ m. We also prefer not more than 5% by  
15 weight of the particles to have a diameter of greater than 10 $\mu$ m, and more preferably not less than 90% by weight of the particles to have a diameter of less than 6 $\mu$ m.

We prefer pressurized compositions to contain from 0.01 to 5%, more preferably from 0.1 to 1%, and most  
20 preferably from 0.1 to 0.5% of finely divided active ingredient.

By "mass median diameter" we mean that half the particulate mass is in particles of lesser diameter and half in particles of greater diameter than the specified  
25 mass median diameter. The mass median diameter is essentially a Stokes diameter and may be determined using a Joyce Loebel sedimentation disc centrifuge either in a two layer or line start photometric mode [Bagness J and Ottaway

A; Proc Soc Analyt Chem, Part 4, Vol 9; (1972) pp83-86].

The liquefied propellant medium, and indeed the total composition, is preferably such that the active ingredient does not dissolve therein to any substantial extent.

5       The liquefied propellant is preferably a gas at room temperature (20°C) and atmospheric pressure, i.e. it should have a boiling point below 20°C at atmospheric pressure. The liquefied propellant should also be non-toxic. Among the suitable liquefied propellants which may be employed  
10 are dimethyl ether and alkanes containing up to five carbon atoms, eg butane or pentane, or a lower alkyl chloride, eg methyl, ethyl or propyl chlorides. The most suitable liquefied propellants are the fluorinated and fluorochlorinated lower alkanes such as are sold under the  
15 Registered Trade Mark 'Freon' (the use of the latter type of propellants is a matter of current concern, and they may be replaced by a suitable substitute when such is available). Mixtures of the above mentioned propellants may suitably be employed. Examples of these propellants  
20 are:

dichlorodifluoromethane ('Propellant 12'),  
1,2-dichlorotetrafluoroethane ('Propellant 114')  
trichloromonofluoromethane ('Propellant 11'),  
dichloromonofluoromethane ('Propellant 21'),  
25 monochlorodifluoromethane ('Propellant 22'),  
trichlorotrifluoroethane ('Propellant 113'), and  
monochlorotrifluoromethane ('Propellant 13').

Propellants with improved vapour pressure

- 10 -

characteristics may be obtained by using certain mixtures of these compounds, eg propellant 11 with propellant 12, or propellant 12 with propellant 114. For example, propellant 12, which has a vapour pressure of about 570kPa (absolute) at 20°C and propellant 114, with a vapour pressure of about 180kPa (absolute) at 20°C, may be mixed in various proportions to form a propellant having a desired intermediate vapour pressure. We prefer compositions which do not contain trichloromonofluoromethane.

10 It is desirable that the vapour pressure of the propellant employed be between 380 and 500, and preferably between 410 and 470kPa (absolute) at 20°C. Such a propellant mixture is usable safely with metal containers. Other mixtures of propellant 12 with propellant 114, or of 15 propellant 12 with propellant 11, or of propellant 12 with propellant 11 and propellant 114 with absolute vapour pressures at 20°C in the range 230 to 380 kPa are usable safely with specially reinforced glass containers.

The pressurized composition may also contain a surface 20 active agent. The surface active agent may be a liquid or solid non-ionic surface active agent or may be a solid anionic surface active agent. It is preferred to use the solid anionic surface active agent in the form of the sodium salt.

25 The preferred solid anionic surface active agent is sodium dioctyl-sulphosuccinate.

The amount of the surface active agent required is related to the solids content of the suspension and to the

particle size of the solids. In general it is only necessary to use 5-15%, and preferably 5-8%, of the solid anionic surface active agent by weight of the solids content of the suspension.

5 When a liquid, non-ionic surface-active agent is employed it should have a hydrophile-lipophile balance (HLB) ratio of less than 10. The HLB ratio is an empirical number which provides a guide to the surface-active properties of a surface-active agent. The lower the HLB  
10 ratio, the more lipophilic is the agent, and conversely, the higher the HLB ratio, the more hydrophilic is the agent. The HLB ratio is well known and understood by the colloid chemist and its method of determination is described by W C Griffin in the Journal of the Society of  
15 Cosmetic Chemists, Vol 1, No 5, pages 311-326 (1949). Preferably the surface-active agent employed should have an HLB ratio of 1 to 5. It is possible to employ mixtures of surface-active agents, the mixture having an HLB ratio within the prescribed range.

20 Those surface-active agents which are soluble or dispersible in the propellant are effective. The more propellant-soluble surface-active agents are the most effective.

We prefer the liquid non-ionic surface-active agent to  
25 comprise from 0.1 to 2%, and more preferably from 0.2 to 1%, by weight of the total composition. Such compositions tend to be more physically stable on storage.

Among the liquid non-ionic surface-active agents which

- 12 -

may be employed are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octoic, lauric, palmitic, stearic, linoleic, linolenic, oleostearic and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride such as, for example, ethylene glycol, glycerol, erythritol, arabitol, mannitol, sorbitol, the hexitol anhydrides derived from sorbitol (the sorbitan esters sold under the Registered Trade Mark 'Span') and the polyoxyethylene and polyoxypropylene derivatives of these esters. Mixed esters, such as mixed or natural glycerides, may be employed. The preferred liquid non-ionic surface-active agents are the oleates of sorbitan, eg those sold under the Registered Trade Marks 'Arlacel C' (Sorbitan sesquioleate), 'Span 80' (Sorbitan monooleate) and 'Span 85' (Sorbitan trioleate). Specific examples of other liquid non-ionic surface-active agents which may be employed are sorbitan monolaurate, polyoxyethylene sorbitol tetraoleate, polyoxyethylene sorbitol pentaoleate, and polyoxypropylene mannitol dioleate.

We particularly prefer compositions containing a sorbitan or sorbitol ester, eg sorbitan trioleate, in a mixture of propellants 12 and 114. We prefer the ratio of propellant 12 to 114 to be in the range from 2:1 to 1:1, and preferably about 1.5:1 by weight, i.e. we prefer an excess of propellant 12 over propellant 114.

We prefer packages containing from about 8 to 30ml of composition, eg a conventional aerosol pressure pack of

10ml. The pack preferably has a valve adapted to deliver unit dosages of between 0.025 and 0.25ml, and preferably 0.05 or 0.1ml, of composition. We prefer the valve to deliver from 2 to 0.02mg, for example 0.2mg of active ingredient and unit doses of these quantities of the drug are provided.

A suitable dose for administration by inhalation is in the range from 0.001 to 0.1mgkg<sup>-1</sup>day<sup>-1</sup>, and preferably 0.01mgkg<sup>-1</sup>day<sup>-1</sup>.

10 The pressurized compositions of the invention may be made by mixing the various components at a temperature and pressure at which the propellant is in the liquid phase and the active ingredient is in the solid phase.

Thus, according to a second aspect of the present invention, there is provided a method of preparing a pharmaceutical pressurized aerosol composition comprising a compound of formula I, as defined above, or a pharmaceutically acceptable derivative thereof, which comprises mixing the finely divided active ingredient with a pharmaceutically acceptable aerosol propellant.

We further provide a pharmaceutical pressurized aerosol composition comprising a compound of formula I as defined above, or a pharmaceutically acceptable derivative thereof.

25 In producing the pressurized compositions and packages of the invention, a container equipped with a valve is filled with a propellant containing the finely-divided active ingredient in suspension. A container may first be

- 14 -

charged with a weighed amount of dry active ingredient which has been ground to a predetermined particle size, or with a slurry of powder in the cooled liquid propellant. A container may also be filled by introducing powder and  
5 propellant by the normal cold filling method, or a slurry of the powder in that component of the propellant which boils above room temperature may be placed in the container, the valve sealed in place, and the balance of the propellant may be introduced by pressure filling  
10 through the valve nozzle. As a further alternative a bulk of the total composition may be made and portions of this bulk composition may be filled into the container through the valve. Throughout the preparation of the product care is desirably exercised to minimise the absorption of  
15 moisture. On operating the valve, the powder will be dispensed in a stream of propellant, which will vaporise providing an aerosol of dry powder.

Turning now to systemic administration, the active ingredient may be formulated together with known adjuvants,  
20 diluents or carriers using conventional techniques to produce tablets or capsules for oral administration to the gastrointestinal tract. Suitable doses for such oral administration are in the range from 0.003 to  $0.3\text{mgkg}^{-1}\text{day}^{-1}$ , for example  $0.03\text{mgkg}^{-1}\text{day}^{-1}$ .

25 According to a third aspect of the present invention, there is provided a method of treatment of reversible obstructive airways disease, which method comprises administration of a therapeutically effective amount of a



compound of formula I as defined above, or a pharmaceutically acceptable derivative thereof, to a person suffering from, or susceptible to, the disease.

The method of treatment according to the invention has the advantage that the compounds of formula I as defined above, or pharmaceutically acceptable derivatives thereof, are more efficacious, less toxic, are longer acting, have a broader range of activity, are more potent, produce fewer side effects, are more easily absorbed or have other useful pharmacological properties, than compounds previously used in the treatment of reversible obstructive airways disease.

The dosage to be administered will of course vary with the particular active ingredient, the condition to be treated and with its severity.

It is preferred that the dose be such as to give a sustained rather than a transitory action.

The active ingredient may be administered as divided doses from 1 to 6, and preferably 2 to 4, times per day.

Each dose may comprise 1 or more unit doses.

A group of compounds which may be mentioned are compounds of formula I as defined above, provided that the compound is not 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo [22.3.1.0<sup>4,9</sup>]octacos-18-ene-2,3,10,16-tetraone, and pharmaceutically acceptable derivatives thereof.

The invention is illustrated, but in no way limited by, the following Examples.

- 16 -

Example APressurized aerosol compositionIngredients

17-propyl-1-hydroxy-12-[2-(4-hydroxy-3-	
5 methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-	
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo	
[22.3.1.0 <sup>4,9</sup> ]octacos-18-ene-2,3,10,16-tetraone	
(mass median diameter less than 3 microns)	0.054
Sorbitan trioleate	0.091
10 Propellant 114	7.099
Propellant 12	<u>10.649</u>
	17.893

Method: the sorbitan ester is dispersed in up to half the propellant 12 at -40°C while stirring with a high dispersion mixer. The finely divided active ingredient is added to the resulting dispersion and disperses in it. The balance of the propellant 12 is then added at -50°C, followed by the propellant 114 also cooled to -50°C. The resulting mixtures are then filled into vials onto which valves, eg metering valves, are subsequently crimped.

Example BPressurized aerosol composition containing FR-900506Ingredients

FR-900506

5	(mass median diameter less than 3 microns)	0.054
	Sorbitan trioleate	0.091
	Propellant 114	7.099
	Propellant 12	<u>10.649</u>
		17.893

- 10 The pressurized aerosol composition was prepared following the method of Example A.

Example CAssay for inhibitory activity against respiratory

- 15 resistance and antigen-induced bronchial  
hyper-responsiveness

Method**(1) Preparation of inhalation-sensitized guinea pigs**

- Male Hartley guinea pigs (weighing about 300g) were  
20 each placed in a plastic inhalation chamber. Using an  
ultrasonic nebulizer (NEU10B, Omron Corporation), an  
aerosolized solution of ovalbumin in physiological saline  
(10mgml<sup>-1</sup>) was introduced into the chamber for 10 minutes  
daily for 10 consecutive days to effect sensitization. The  
25 animals were used in the experiments 5 days after  
establishment of sensitization.

**(2) Pretreatment with FR-900506**

During the period from the first day of sensitization

- 18 -

to the day before an antigen challenge, the animals were orally treated with a  $1\text{mgml}^{-1}$  solution of FR-900506 (in ethanol/olive oil [2:78 v/v]) every other day. Control animals received the ethanol/olive oil vehicle alone in the same manner.

### (3) Experimental schedule

The experimental period was 5 days from day 1 to day 5, and the inhalation challenge with the antigen was given on day 2.

On day 1, and 30 minutes before antigen inhalation challenge on day 2, metopirone (an endogenous cortisol synthesis inhibitor) was intravenously administered ( $10\text{mgkg}^{-1}$ ). So that the animals could tolerate the antigen at comparatively high concentrations, chlorpheniramine maleate, an antihistaminic, was intraperitoneally administered ( $10\text{mgkg}^{-1}$ ) following the second dose of metopirone. After the pretreatment discussed above, each guinea pig was transferred to an animal box connected to an oscillator and fixed therein with its head projecting out. The head was then covered with an aerochamber communicating with a Devilvis 646 nebulizer.

### (4) Assay for respiratory resistance

The assay for respiratory resistance was performed by the oscillation method of Mead et al with some modification (Allergy, 37, 10, 980-991, 1988). The antigen inhalation challenge was made by nebulizing a saline solution of ovalbumin ( $20\text{mgml}^{-1}$ ) with  $5\text{lmin}^{-1}$  of air and causing

the animals to inhale for 1 minute. The results are shown in Table 1.

(5) Assay for antigen-induced bronchial hyper-responsiveness to acetylcholine

5 Guinea pigs prepared by the method described above were placed in an animal box as described above and the baseline respiratory resistance was measured. The animals were then caused to inhale a nebulized saline solution of acetylcholine (in an ascending concentration series of 156  
10 to  $5000\mu\text{gml}^{-1}$ ) for 1 minute at each concentration until the respiratory resistance was increased to twice the baseline value. From the concentration-resistance curve constructed from the acetylcholine concentration and respiratory resistance data, the acetylcholine  
15 concentration necessary for increasing the respiratory resistance to twice the baseline value [ie  $\text{PC}_{200}\text{-Ach}$  ( $\mu\text{gml}^{-1}$ )] was calculated. The results are shown in Table 2.

(6) Analysis of data

20 The results are expressed as mean  $\pm$  SEM. Student's t-test was used as the test for significant difference.

- 20 -

Results

Table 1: Inhibitory effect of FR-900506 on respiratory resistance (%)

5	Time after antigen inhalation challenge (hrs)	<u>Change in respiratory resistance(%)</u>	
		Control (n=15)	FR-900506 treated (n=7)
	3	131 ± 10	*95 ± 7.3
	6	185 ± 18	*115 ± 9.5
10	9	152 ± 14	*108 ± 4.3

\*P&lt;0.05

Change in respiratory resistance (%)

= Respiratory resistance after challenge x 100%Respiratory resistance before challenge

15

Table 2: Inhibitory effect of FR-900506 on antigen induced hyper-responsiveness to acetylcholine

20	Time after antigen inhalation challenge (hrs)	<u>PC<sub>200</sub>-Ach (μgml<sup>-1</sup>)</u>	
		Control (n=15)	FR-900506 treated (n=7)
	Before challenge	1866 ± 313	1192 ± 358
	24	NS [ 553 ± 80 ] *	NS [ 883 ± 191 ] NS
25	72	[ 1353 ± 196 ] *	[ 1492 ± 354 ] NS

\*P&lt;0.001

NS = no significant difference

The results indicate that the compounds of formula I

- 21 -

are likely to be most efficacious in the treatment of reversible obstructive airways disease.

Example D

Acute toxicity of FR-900506

- 5        An acute intraperitoneal toxicity study of FR-900506 in ddy mice revealed no deaths at  $100\text{mgkg}^{-1}$

10


15

20

25

CLAIMS:

1. The use of a compound of formula I,



wherein  $R^1$  and  $R^2$  together represent two vicinal hydrogen atoms, or form a second bond between the vicinal carbon atoms to which they are attached;

$R^3$  represents H, OH, alkoxy or protected hydroxy;

20  $R^4$  represents OH;

$R^5$  represents H, alkyl or alkenyl;

$R^6$  and  $R^7$  independently represent O, (H,OH), (H,protected hydroxy) or (H,alkoxy);

X and Y independently represent O, (H,OH) or (H,H);

25 n is 1 or 2;

or a pharmaceutically acceptable derivative thereof;

as active ingredient in the manufacture of a medicament for the treatment of reversible obstructive



airways disease.

2. The use according to claim 1, wherein R<sup>5</sup> is selected from allyl, propyl, ethyl and methyl.

3. The use according to claim 1 or claim 2, wherein at least one of R<sup>6</sup> and R<sup>7</sup> represents (H,OH).

4. The use according to any one of the preceding claims, wherein Y represents O.

5. The use according to any one of the preceding claims, wherein n is 2.

6. The use according to claim 1, wherein the compound of formula I is:

- 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,18-dioxa-4-azatricyclo[22.3.1.0<sup>4,9</sup>]octacos-18-ene-2,3,10,16-tetraone,
- 17-ethyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0<sup>4,9</sup>]octacos-18-ene-2,3,10,16-tetraone,
- 17-allyl-1,14-dihydroxy-12-[2-(3,4-dihydroxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0<sup>4,9</sup>]octacos-18-ene-2,3,10,16-tetraone,
- 17-ethyl-1,14-dihydroxy-12-[2-(3,4-dihydroxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0<sup>4,9</sup>]octacos-18-ene-2,3,10,16-tetraone,
- 17-propyl-1-hydroxy-12-[2-(4-hydroxy-3-

- methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-  
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo  
[22.3.1.0<sup>4,9</sup>]octacos-18-ene-2,3,10,16-tetraone,  
17-allyl-1,2,14-trihydroxy-12-[2-(4-hydroxy-3-  
5 methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-  
13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo  
[22.3.1.0<sup>4,9</sup>]octacos-18-ene-3,10,16-trione, or  
17-allyl-1-hydroxy-12-[2-(4-hydroxy-3-  
methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-  
10 13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo  
[22.3.1.0<sup>4,9</sup>]octacos-18-ene-2,3,10,16-tetraone.
7. A pharmaceutical pressurized aerosol composition  
comprising a compound of formula I as defined in any one of  
the preceding claims, or a pharmaceutically acceptable  
15 derivative thereof.
8. A method of preparing a pharmaceutical aerosol  
composition comprising a compound of formula I as defined  
in any one of claims 1 to 6, or a pharmaceutically  
acceptable derivative thereof, which comprises mixing the  
20 finely divided active ingredient with a pharmaceutically  
acceptable aerosol propellant.
9. The use according to any one of claims 1 to 6, wherein  
the disease is asthma.
10. A method of treatment of reversible obstructive  
25 airways disease, which comprises administration of a  
therapeutically effective amount of a compound of formula I  
as defined in any one of claims 1 to 6, or a  
pharmaceutically acceptable derivative thereof, to a person

. suffering from, or susceptible to, the disease.

5

10

15

20

25

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 90/00866

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC <sup>5</sup> :      A 61 K 31/40, A 61 K 31/445		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
IPC <sup>5</sup>	A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	Immunol. Today, volume 10, no. 1, January 1989, Elsevier Science Publishers Ltd, (GB), A.W. Thomson: "FK-505-how much potential?", pages 6-9 see the whole article --	1-9
Y	EP, A, 0315978 (SANDOZ) 17 May 1989 see the whole document, especially page 3, line 47 - page 4, line 1; page 6, line 30 - page 7, line 20 --	1-9
Y	Allergy, volume 40, 1985, C. Pedersen et al.: "Inhibitory effect of cyclosporin A on histamine release from human leukocytes and rat mast cells", pages 103-107 see the whole article --	1-9
Y	La Médecine Infantile, volume 93, no. 3, November 1986, Maloine S.A. édit., J.L. Menardo et al.: "Le traitement ./.	1-9
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p><sup>10</sup> Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
23rd August 1990	28.09.90	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	F.W. HECK	

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

	prophylactique de l'asthme", pages 745-753 see page 749, left-hand column, line 53 - right-hand column, line 5 --	
P,Y	EP, A, 0327009 (FUJISAWA PHARM.) 9 August 1989 see the whole document cited in the application --	1-9
Y	EP, A, 0184162 (FUJISAWA PHARM.) 11 June 1986 see the whole document cited in the application -----	1-9

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 10 because they relate to subject matter not required to be searched by this Authority, namely:  
see PCT Rule 39.1.(iv)

2. ☐ Claim numbers ..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers ..... because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9000866  
SA 37366

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 24/09/90  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0315978	17-05-89	AU-A- 2490288	11-05-89
		DE-A- 3838035	18-05-89
		GB-A- 2212061	19-07-89
		JP-A- 1157913	21-06-89
		NL-A- 8802734	01-06-89
		SE-A- 8804036	08-11-88
EP-A- 0327009	09-08-89	JP-A- 1304888	08-12-89
EP-A- 0184162	11-06-86	AU-B- 592067	04-01-90
		AU-A- 5059685	12-06-86
		JP-A- 61148181	05-07-86
		US-A- 4894366	16-01-90
		US-A- 4929611	29-05-90

EPO FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82